Aurobindo Pharma reports ₹8,853 crore revenue for Q4FY26 with 5.6% growth

Yash Agarwal — Thu, 21 May 2026 15:13:58 +0000

Aurobindo Pharma Limited has announced its consolidated financial results for the fourth quarter and the fiscal year ending March 31, 2026. The company reported a 5.6% year-on-year increase in revenue from operations, reaching ₹8,853 crore in Q4FY26, compared to ₹8,382 crore in Q4FY25.

The European business was a significant contributor to this growth, achieving a milestone of over €1 billion in revenues for FY26. The revenue for the European segment increased by 30.2% year-on-year to ₹2,795 crore during the quarter. Additionally, the Growth Markets segment saw a 24.7% increase in revenue, reaching ₹980 crore.

The Active Pharmaceutical Ingredients (API) segment also performed well, with a 12.9% year-on-year increase in revenues to ₹1,208 crore, contributing 13.6% to the consolidated revenue. The ARV segment saw a 6.4% increase in revenue, amounting to ₹328 crore.

The company’s EBITDA before R&D expenses stood at ₹2,165 crore, with an EBITDA margin of 24.5%. The net profit for the quarter was ₹921 crore, reflecting a 2.0% increase from the previous year. The basic and diluted earnings per share (EPS) were reported at ₹15.86.

Aurobindo Pharma also highlighted its strong net cash position as of March 31, 2026, following the acquisition of Khandelwal Laboratories’ non-oncology business for USD 317 million. The company generated free cash flows of USD 35 million during the quarter.

Commenting on the results, Mr. K. Nithyananda Reddy, Vice-Chairman and Managing Director, expressed satisfaction with the company’s performance, citing consistent volumes, improved operating efficiencies, and disciplined execution as key factors contributing to the positive results.

Disclaimer: This article is based on a regulatory filing submitted to the National Stock Exchange of India (NSE).

K. Nithyananda Reddy | Business Upturn

Aurobindo Pharma reports ₹8,853 crore revenue for Q4FY26 with 5.6% growth